Harm reductions of 20% or >= 50% were detected with adequate power by those CRR scenarios with at least 100 and 500 harm incidents respectively. The number of detected harm incidents was dependent on the baseline harm rate multiplied by: the period of time reviewed in each record; number of records reviewed per practice; number of practices who reviewed records; and the number of times each record was reviewed.

Conclusion: We developed Epigenetics inhibitor a simple formula to calculate the minimum

values of CRR parameters required to achieve adequate precision and acceptable power when monitoring harm rates. Our findings have practical implications for health care decision-makers, leaders SB203580 molecular weight and researchers aiming to measure and reduce harm at regional or national level.”
“Purpose. The Pain Vigilance and Awareness Questionnaire (PVAQ) has been shown to be a reliable measure for assessing attention to pain. Different factor structures have been reported in Western populations;

yet, whether the known factor models could be replicated in non-Western populations and the psychometric properties of the scale remain unclear. This study aimed to examine the factorial validity and psychometric properties of the Chinese version of the PVAQ (ChPVAQ).

Methods. A total of 242 Chinese patients with chronic pain completed the ChPVAQ, the Chronic Pain selleck compound Grade questionnaire, the Chinese version of the 11-item version of the Tampa Scale for Kinesiophobia (ChTSK-11), the Hospital Anxiety and Depression Scale (HADS), and questions assessing socio-demographic characteristics.

Results. Results of confirmatory factor analyses showed that of the nine competing models tested, McCracken’s two-factor correlated model for the 13-item version of PVAQ (PVAQ-13) demonstrated the best data-model fit (CFI = 0.93). The two sub-scales and the entire scale of ChPVAQ-13

obtained moderately high internal consistency (Cronbach’s alpha s: 0.75-0.77). The ChPVAQ-13 scales showed significant positive correlations with HADS, ChTSK11, pain intensity, and disability scores. Results of hierarchical multiple regression analyses showed the ChPVAQ-13 scales predicted concurrent depression (F[4,187] = 6.01, P < 0.001) and pain disability (F[4,190] = 3.54, P < 0.05) scores. Passive Awareness emerged as significant independent predictor of concurrent depression (standardized beta coefficient [std beta] = 0.17, P < 0.05) and pain disability (std beta = 0.24, P < 0.01), while Active Vigilance (std beta = 0.19, P < 0.05) predicted concurrent pain disability.

Conclusions. Our results offer preliminary evidence for the factorial validity and reliability the ChPVAQ-13.

No related posts.